Clinical trial for Parkinson's disease?
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008959:Models, Neurological; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011446:Prospective Studies; D011725:Pyridines / Q000633:toxicity; D011726:Pyridinium Compounds / Q000633:toxicity; D012642:Selegiline / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D011725:Pyridines; D011726:Pyridinium Compounds; D012642:Selegiline; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium